ADMA Biologics, Inc.

NASDAQ:ADMA

Biotechnology

Healthcare
$13.34 +0.42%

+$0.04 today

Market cap
$2.96B
Beta
0.73
P/E (TTM)
12.1
EPS (TTM)
$0.70
52W Low $7.21High $20.46

Volume 3.62M

Average 7.07M

Returns on capital

ADMA Biologics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

30.8%

avg -226.3%

ROIC

27.6%

avg -29.9%

ROA

23.5%

avg -30.6%

Analysis

ROE is currently the strongest return metric at 30.8% versus its period average of -226.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Adam S. Grossman

Co-Founder, President, Chief Executive Officer & DirectorUSD 2.14M49585.95K0.25%

Kaitlin Kestenberg

Chief Operating Officer & Senior Vice President of ComplianceUSD 988.66K39——

Jerrold Grossman

Co-Founder & Vice Chairman of the BoardUSD 90K78——

Terence Kohler

Chief Financial Officer & TreasurerUSD 46.97K———

Skyler Bloom

Senior Director of Business Development & Corporate Strategy————

Michael Goldstein

General Counsel————

John Hafl

Executive Director of Sales————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 5, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

5

$468,294.00

Sells

9

$2.99M

Net Transaction Value

−$2.53M

Net selling

Most Active

Grossman Adam S

8 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 5, 26

Grossman Adam S

Direct

Sell$1.3M
Nov 5, 26

Grossman Adam S

Direct

Sell$504K
May 27, 26

Grossman Jerrold B

Direct

Buy$50.6K
May 12, 26

Grossman Jerrold B

Direct

Buy$100.1K
May 11, 26

Grossman Jerrold B

Direct

Buy$100.1K
Mar 16, 26

Grossman Adam S

Direct

Sell$227.4K
Mar 16, 26

Grossman Adam S

Direct

Sell$91K
Mar 9, 26

Kestenberg-Messina Kaitlin M.

Direct

Sell$157.8K
Mar 6, 26

ELMS STEVE

Indirect

Buy$107.7K
Mar 5, 26

ELMS STEVE

Indirect

Buy$109.7K

1–10 of 14

Summary

Insiders reported 5 buys worth $468,294.00 and 9 sells worth $2.99M over the last 12 months. That adds up to net selling of $2.53M. Grossman Adam S was the most active insider with 8 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
+22.1% (5yr)1 analysts
RevenueN/AN/A+49.0%
+11.9% (5yr)2 analysts
Net IncomeN/AN/AN/A
+22.1% (5yr)2 analysts
EBITN/AN/AN/A
+22.1% (5yr)2 analysts

Analysis

Recent growth has been strongest in Revenue at +49.0% over three years. Forward estimates point to EBIT at +22.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does ADMA Biologics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ADMA's management, answered from reported figures.

Who manages ADMA?

ADMA Biologics, Inc. (ADMA) lists 7 active executives. The top listed executive is Jerrold Grossman, Co-Founder & Vice Chairman of the Board.

Are ADMA insiders buying or selling?

Recent insider activity shows net selling of $3.66M.